FTC targets ‘junk’ patents including Novo’s Ozempic, GSK’s Trelegy Ellipta and other drugs
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.